This article was originally published on Cancer Network Treatment options for multiple myeloma only continued to improve over the course of 2020, even with the development of the coronavirus disease 2019 (COVID-19) pandemic. Advancements such as the approval of selinexor (Xpovio) in combination with bortezomib (Velcade) and dexathamethasone for the treatment of adults with multiple myeloma who...Continue Reading